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compared to the anticoagulants it had the highest incremental net monetary benefit 
compared with warfarin; £596 (£-6,494 to £4,524). This was due to the low cost and 
risk of adverse events of aspirin. All other comparators had a negative incremental 
net monetary benefit compared with warfarin. ConClusions: For acute treatment, 
apixaban had the highest probability (57%) of being cost-effective at a willingness to 
pay threshold of £20,000 for acute treatment. Novel oral anticoagulants are unlikely 
to be cost-effective for long term use in secondary prevention.
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objeCtives: Worldwide, stroke is the third most common cause of death in devel-
oped countries with declining death rates. In Austria the incidence rate of stroke 
is 2.1 – 2.3 per thousand annually. Cerebrolysin prevents acute neuronal damage 
and accelerates recovery after stroke. The purpose of this analysis was to deter-
mine costs of stroke for Austria in general and to estimate the cost-effectiveness 
of Cerebrolysin in combination with alteplase compared to alteplase alone. The 
analysis should assess health economic advantages in the acute care due to a faster 
improvement in neurological impairment and for rehabilitation in early post-acute 
phase and quantify the correlated reduced resource use in the health care and 
social system. Methods: A Markov-model was developed based on the mRS 
states 90 days after stroke to simulate consequences over a 10-year time-horizon. 
Consequences include recurrent stoke, deteriorated mRS, death due to recurrent 
stroke or other reasons. Health benefits were measured in quality-adjusted life years 
(QALYs) and life years (LYs). Monte-Carlo-simulation accounted for uncertainty. 
Probabilities were derived from RCTs and open-label studies; direct costs (2014) 
were derived from published sources from the payer’s perspective. QALYs, life years 
and costs were projected over a 10 year time-horizon. Costs and outcomes were 
discounted according to the national guidelines Results: Austrian costs associated 
with Cerebrolysin amount to € 61,468.67 and generate 3.77 QALYs and 6.70 LYs. Costs 
without Cerebrolysin amount to € 62,257.88, achieve 3.75 QALYs and 6.70 LYs. The 
treatment strategy with Cerebrolysin dominates the strategy without Cerebrolysin. 
Assessing the disaggregated costs it becomes apparent that costs savings are due to 
lower acute stroke costs (€ -493.29) and nursing-home costs mainly after first stroke 
(€ -250.88). ConClusions: From a health economic perspective, Cerebrolysin is a 
cost-effective therapy; it mainly reduces event costs due to early remobilization 
and, in addition, rehabilitation and nursing-home cost.
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objeCtives: A novel pharmacist guided pharmacogenetic service (PGx) for patients 
newly started on warfarin has been implemented at the University of Illinois 
Hospital & Health Science System (UI-Health). Although the PGx service was found 
to be more effective in reducing bleeding and thrombosis related hospitalizations 
at 90 days post warfarin initiation compared to usual care, the cost of the genotype 
test and the PGx consult service warrants economic evaluation beyond 90-days 
of follow-up. The objective of this study was to evaluate the long-term cost-effec-
tiveness of this novel pharmacist guided warfarin PGx service compared to usual 
care. Methods: A cost-effectiveness model was developed in TreeAge Pro 2014, 
Williamstown, MA, USA. Patients in either the PGx or the usual care cohort followed 
by UI-health were included as comparators and costs and QALYs were estimated 
over a 5 year horizon. Warfarin related (i.e., bleeding or thrombosis) readmissions 
at 30 and 90 days were modeled in a decision tree. Patients in the model without 
a fatal event within 90 days transitioned to a Markov model with a 3-month cycle. 
For patients with venous thromboembolism, the Markov states included well, post 
intracranial hemorrhage (ICH), post thrombotic syndrome, and dead, whereas those 
with atrial fibrillation included well, post ICH, post stroke, post myocardial infarc-
tion and dead. Utilities, cost inputs and transition probabilities were taken from the 
literature and an annual 3% discount rate was used. Results: At 5 years, patients 
managed by the PGx service had expected costs of $7412 and gains of 4.41 QALYs 
whereas those who received usual care had expected costs of $7926 and gains of 
4.39 QALYs. ConClusions: A novel pharmacist guided warfarin pharmacogenetic 
service was projected to be cost-saving and to result in similar or higher QALYs by 
reducing hospitalizations due to warfarin related adverse events.
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objeCtives: To assess the cost-effectiveness of edoxaban versus standard ther-
apy (low molecular weight heparin overlapped and followed by acenocoumarol) 
in patients with venous thromboembolism (VTE), including deep vein thrombosis 
(DVT) and pulmonary embolism (PE). Methods: A Markov model was developed 
to describe the management and consequences of VTE for Spain. We defined a 
cycle’s length of 2 weeks and different health states to simulate the natural history 
of VTE patients after suffering DVT and/or PE. Patients were treated with edoxaban 
or standard therapy for 3, 6 and 12 months, 12 month treatment period being our 
base case scenario. We used the HOKUSAI study and related literature to obtain 
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objeCtives: To evaluate the cost-effectiveness of using levosimendan compared 
with dobutamine, in the perioperative treatment of patients undergoing cardiac 
surgery who require inotropic support. Methods: A two-part Markov model was 
designed to simulate health state transitions of patients undergoing cardiac sur-
gery, and estimate the short- and long-term health benefits of treatment. Hospital 
length of stay (LOS), mortality, medication and adverse events were key clinical 
and cost inputs. Treatment cost-effectiveness was evaluated in terms of costs, 
incremental cost per Life Years (LYs), and incremental cost per Quality-Adjusted 
Life Years (QALYs) gained within the German healthcare system. Drug prices were 
calculated from the German Drug Directory (€ /2014) and published literature, with 
a 3% yearly discount rate applied. The base case analysis was for a one year time 
horizon. Results: The use of levosimendan versus dobutamine was associated 
with cost savings of € 4787 per patient from the German hospital perspective. These 
cost savings were due to reduced adverse events and shorter hospital LOS, lead-
ing to increased bed capacity and hospital revenue. Excluding revenue gains, the 
incremental cost per LY was € 9115 and incremental cost per QALY was € 11,919 
for levosimendan versus dobutamine. Levosimendan was 95% to 100% likely to 
be cost-effective at a willingness to pay threshold of € 20,000 to € 40,000 per QALY. 
Probabilistic sensitivity analyses demonstrated that results were robust to param-
eter changes. ConClusions: The use of levosimendan in patients undergoing 
cardiac surgery who require inotropic support is cost-effective and potentially 
cost-saving compared with dobutamine.
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objeCtives: Thyroid function testing during amiodarone therapy is recommended 
every 6 months in order to control for the risk of hypothyroidism and thyrotoxicity, 
although evidence of the effect of regular monitoring on the risk of amiodarone-
related ADEs, cost and utility is sparse. This study investigated the cost-effectiveness 
of alternative frequency of monitoring amiodarone therapy in UK general prac-
tice. Methods: A cost-effectiveness analysis compared alterative frequency of 
monitoring (once in 6 months (recommended frequency), less than once in 6 months 
(less frequent), more than once in 6 months (more frequent)). A Markov model with 
cycle length of 90 days and 5 year horizon simulated progression through the ADE 
pathway (hypothyroidism, thyrotoxicity, cardiac complications). Treatment effect 
of monitoring on risk of ADE was estimated from UK GP and hospital observational 
data. Propensity score weights were used to control for non-random assignment. 
Probabilities, utilities and costs were derived from literature on amiodarone-related 
toxicity, with priority given to UK based-studies. Cost and utility was assessed from 
the perspective of NHS England and discounted at 3.5% per annum. A probabil-
istic sensitivity analysis (PSA) estimated the effect of parametric uncertainty on 
incremental cost and effect. Results: Recommended frequency monitoring was 
the dominant strategy. Mean incremental QALYs: 0.036 (95%CI -0.066,0.075), 0.039 
(-0.068,0.085); mean additional cost: -£6 (-283,272), -£61 (-360,238) vs. less frequent 
and more frequent monitoring, respectively. However, due to small differences in 
QALY and cost generated and significant uncertainty in model parameters, the prob-
ability of cost-effectiveness was 41% at £20,000/QALY threshold. ConClusions: 
The analysis supported the current recommendation for 6-monthly monitoring of 
thyroid function in amiodarone therapy, although the confidence in this conclusion 
was low due to poor evidence on the risk of amiodarone-related thyroid ADEs and 
their economic effect. Additional investigation of amiodarone monitoring is needed 
in order to justify its application in primary care.
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objeCtives: This study estimated the cost-effectiveness of novel oral anticoagu-
lants for (i) acute treatment and (ii) secondary prevention, of VTE from the perspec-
tive of the NHS. Methods: Secondary prevention:A Markov model was developed 
to evaluate cost-effectiveness of aspirin, rivaroxaban, dabigatran, warfarin (INR 2-3), 
apixaban 2.5mg and apixaban 5mg, compared to “no pharmacotherapy”. Acute treat-
ment: A decision tree model for short term outcomes, followed by the secondary pre-
vention model for long-term consequences, was used to evaluate cost-effectiveness 
of dabigatran, rivaroxaban, apixaban and edoxaban, compared with warfarin (INR 
2-3). All interventions were considered at the licensed dose(s). Efficacy and safety 
parameters were informed by network meta-analyses and longitudinal studies were 
used to parameterise the long term follow up. The models had a life time horizon 
with costs and QALYs discounted at 3.5%. Results: All results are presented at a 
£20,000 willingness to pay per QALY threshold Acute treatment:Apixaban showed 
the highest expected QALYs (12.02) and was the most cost-effective intervention 
with an incremental net monetary benefit of £645 (£-1,274 to £2,100) compared to 
Warfarin. Rivaroxaban also had a positive incremental net benefit (£167); all other 
comparators had a negative incremental net monetary benefit compared with war-
farin. Secondary prevention:Although aspirin has a higher risk of recurrent VTE 
